Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis

a.lsfakia shared this article with you from Inoreader Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis Via Journal of Digestive Diseases Objectives To assess the effect of donor selection, stool procedures and pretreatment with antibiotics on the efficacy and safety of fecal microbiota transplantation (FMT)‐treated ulcerative colitis (UC). Methods A systematic review and meta‐analysis was conducted including studies on UC treated with FMT as the primary therapeutic agent published up to June 30, 2020. Primary end‐point data included clinical remission (CR) or CR combined with endoscopic remission. Results A total of 37 studies (seven random controlled trials [RCTs], five controlled and 25 uncontrolled cohort studies) and 959 patients with UC were enrolled. In controlled cohort studies and RCTs, FMT had a significantly greater benefit than placebo (pooled odds ratio [P‐OR] 3.392, 95% CI 2.196‐5.240, P < 0.001), with no heterogeneity (I 2 = 0%). Furthermore, administration of FMT via the lower gastrointestinal (GI) tract was more effective in achieving CR than via the upper GI tract (44.3% vs 31.7%). The remission rate was also higher when the total stool dosage was over 275 g compared with less than 275 g (51.9% vs 29.5%). Overall, the incidence of serious adverse events of FMT was 5.9%. There was no significant difference between single and multiple donors, fresh and frozen stool sample used, and whether or not antibiotic pretreatment was administered before FMT. Conclusion FMT administration via the lower GI tract and using higher dosage appear to be effective and safe in inducing remission of active UC. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.